We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: RNAi Firm Raises Funds to Develop Drugs That Turn Off Disease-Causing Genes
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > RNAi Firm Raises Funds to Develop Drugs That Turn Off Disease-Causing Genes
FinanceMedical InnovationsTechnology

RNAi Firm Raises Funds to Develop Drugs That Turn Off Disease-Causing Genes

Deanna Pogorelc
Deanna Pogorelc
Share
2 Min Read
SHARE

RNAiFirst published on MedCityNews.com. Just a few years ago, several big companies abandoned their RNAi drug development efforts, finding it difficult to deliver drugs that use the RNAi method for silencing genes.

RNAiFirst published on MedCityNews.com. Just a few years ago, several big companies abandoned their RNAi drug development efforts, finding it difficult to deliver drugs that use the RNAi method for silencing genes. Recently, though, the market seems to be on the rebound.

A San Diego startup developing a siRNA drug delivery system for the orphan disease market is further evidence of that. To expand its team and work toward choosing a lead clinical candidate next year, Arcturus Therapeutics has just rounded up $5 million from angel investors in Canada, Japan and the United States.

RNA interference is a technique that uses small snippets of RNA to silence a cell’s expression of genes and viruses that cause disease. Arcturus is developing a lipid nanoparticle drug delivery system that leverages small interfering RNA, which can bind to specific messenger RNA molecules and increase or decrease their activity. It’s using that system to develop a pipeline of new therapeutics for orphan diseases, beginning with a rare liver disease.

More Read

plastic surgery
The Effects of Technology on Plastic Surgery
BioPharma Beat: A Data-Driven History of Bioinformatics
Can You Hear Me Now? Another Health Market that Really Works
New Technologies Are Defining Health Information Management
Marketing Home Health Care: A Major Opportunity in the United States

Since its $1.3 million seed round closed early this summer, the company has licensed a portfolio of Marina Biotech’s unlocked nucleic acid technology.

Two former employees of Nitto Denko, Joseph Payne and Pad Chivukula, started Arcturus earlier this year. It’s one of 18 life sciences companies located at Janssen Labs, an innovation center in San Diego that provides startups access to wet labs and research and administrative equipment.

Global Industry Analysts estimates that the market for RNAi technologies, with leaders like Alnylam Pharmaceuticals and Silence Therapeutics, will reach $4 billion by 2017.

TAGGED:RNA
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

ID-10010630
BusinessFinance

Clarifying the ICD-10 Implementation Process

April 27, 2015
Image
FinanceHealth Reform

Leapfrog Exposes High Cost of Hospital Rework

July 28, 2013

Turning Health Data into Health Narrative: Interview with Dr. Leslie Saxon on Digital Health

October 28, 2013

The PCMH and Home Care Data: An Interview with Melissa McCormack

December 19, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?